Actively Recruiting
Phase 2 Study of 9MW2821 Alone or With PD-1 Inhibitor for Advanced or Metastatic Triple-Negative Breast Cancer
Led by Mabwell (Shanghai) Bioscience Co., Ltd. · Updated on 2025-01-10
160
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of the drug 9MW2821 alone or combined with a PD-1 inhibitor in people with locally advanced or metastatic Triple-Negative Breast Cancer who are not suitable for radical therapy. This Phase 2, open-label study aims to understand how well these treatments work and how safe they are for this condition. Participants receive intravenous infusions of 9MW2821 alone or in combination with a PD-1 inhibitor according to the study protocol. The study includes different treatment groups one with 9MW2821 alone, one with 9MW2821 plus a PD-1 inhibitor, and one where participants may receive either 9MW2821 alone or combined with a PD-1 inhibitor. The treatments are given as part of a randomized design without masking. Throughout the study, participants will have their response to treatment measured up to 24 months, including detailed assessments of tumor response, duration, and control of the disease. Researchers will also monitor survival, drug levels in the body, and any immune reactions. Participants must undergo tumor tissue testing and have regular evaluations to track treatment effects and safety during the study period.
CONDITIONS
Brief Title
A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
Research Team
J
Jian Zhang, Professor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here